title: Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.
abstract: Plasma amyloid beta42 peptide (Abeta42) levels are significantly elevated in all genetic forms of early-onset Alzheimer's disease caused by familial Alzheimer's disease mutations or Down's syndrome. Moreover, recent studies have determined that both plasma Abeta42 and Abeta40 levels are significantly elevated in late-onset Alzheimer's disease (LOAD) patients, their cognitively normal first-degree relatives, and members of typical LOAD families when compared to appropriate controls. To determine the magnitude of the genetic component affecting plasma Abeta levels, we estimated the heritability of plasma Abeta42 and Abeta40 in 15 extended, multigenerational LOAD pedigrees, using a variance components method. Heritability estimates as high as 73 and 54% were found for plasma Abeta42 and Abeta40 levels, respectively. Inclusion of the ApoE epsilon4 dosage as a covariate was not found to have a significant effect on the heritability of these traits. These results suggest that genetic determinants other than ApoE account for a very substantial percentage of the phenotypic variance in plasma Abeta levels. The high heritability and the significant elevation of these traits in LOAD pedigrees suggest that at least some of the genetic determinants of plasma Abeta levels may lead to elevated Abeta and LOAD in these families. Thus, we suggest that plasma Abeta levels are quantitative traits that may be excellent surrogate markers for use in linkage analysis to identify loci that are important in typical LOAD.
authors.affiliation: Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, USA.
authors.forename: N
authors.initials: N
authors.lastname: Ertekin-Taner
authors.forename: N
authors.initials: N
authors.lastname: Graff-Radford
authors.forename: L H
authors.initials: LH
authors.lastname: Younkin
authors.forename: C
authors.initials: C
authors.lastname: Eckman
authors.forename: J
authors.initials: J
authors.lastname: Adamson
authors.forename: D J
authors.initials: DJ
authors.lastname: Schaid
authors.forename: J
authors.initials: J
authors.lastname: Blangero
authors.forename: M
authors.initials: M
authors.lastname: Hutton
authors.forename: S G
authors.initials: SG
authors.lastname: Younkin
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood* / Q000235:genetics*; D016229:Amyloid beta-Peptides / Q000097:blood* / Q000235:genetics*; D000704:Analysis of Variance; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics; D002874:Chromosome Mapping / Q000379:methods; D004314:Down Syndrome / Q000150:complications / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D008875:Middle Aged; D008957:Models, Genetic; D009154:Mutation / Q000235:genetics; D010375:Pedigree; D010446:Peptide Fragments / Q000097:blood* / Q000235:genetics*; D010641:Phenotype
chemical_list: D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D005819:Genetic Markers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)